Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights

Mar 16, 2020

Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

Mar 16, 2020

Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

Mar 11, 2020

Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option

Feb 24, 2020

Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

Feb 18, 2020

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

Feb 13, 2020

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

Feb 11, 2020

Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

Jan 22, 2020

Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

Jan 16, 2020

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Jan 13, 2020
RSS
  • Prev
    • 1...
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • ...45
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2022 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap